HOME >> BIOLOGY >> NEWS
Positive attitude is best prevention against heart disease

"This study has the potential to change how emergency departments triage patients with chest pain." Nisha Chandra-Stobos, M.D.

For years, hospital emergency physicians have used nitrogylcerin as a gold standard for identifying heart disease as a cause of chest pain. If a patient presents with chest pain, and a nitroglycerin pill or spray under the tongue relieves the pain within a few minutes, the likely diagnosis is coronary artery disease (CAD).

Now a Johns Hopkins study is challenging that belief. Of 459 patients who came to the emergency department at Hopkins' Bayview Medical Center between February and June of this year complaining of chest pain, nitroglycerin relieved chest pain in about 39 percent of patients, whether or not they turned out to have heart disease. Overall, nitroglycerin was only 28 percent accurate in predicting CAD as the source of pain. These findings will be presented Nov. 12 at the American Heart Association's annual Scientific Sessions in Anaheim, Calif.

"This study has the potential to change how emergency departments triage patients with chest pain," says Nisha Chandra-Stobos, M.D., senior author of the study and director of the coronary intensive care unit at Bayview. "Our data suggest that despite the commonly held belief, pain relief with nitroglycerin does not predict coronary artery disease and should not be used to guide diagnosis."

Nitroglycerin works by relaxing the veins (reducing the amount of blood that returns to the heart and easing the heart's workload) and arteries (increasing the heart's blood supply). It's the drug most often used for the one in five patients who comes to the ED complaining of chest pain.

The patients studied had an average age of 58. Forty-six percent were male; 44 percent were smokers; 25 percent were diabetic and 38 percent had a known history of CAD. After initial treatment with nitroglycerin, 261 (57 percent) underwent further cardiac test
'"/>

Contact: Karen Blum
kblum@jhmi.edu
410-955-1534
Johns Hopkins Medical Institutions
13-Nov-2001


Page: 1 2

Related biology news :

1. Positive attitude is best prevention against heart disease
2. Nationwide Study Finds HIV-Positive Women Are At High Risk For Cervical Human Papillomavirus Infection
3. Native Gray Ants Play Positive Role In Valley Peach Orchards
4. Drug Therapy Shows Promise In Preventing Hepatitis Infection In Transplant Recipients Who Receive Hepatitis B Positive Livers, Says One Study
5. HIV-Positive Injection Drug Users Often Dont Receive Protease Inhibitors And May Not Be Aware Of The Drug
6. Long-Term Study Looks At HIV Positive Men With Few Signs Of Disease Progression, 10-18 Years After Seroconversion
7. Study finds wide attitude gap on wolves
8. Study reveals differing attitudes to PGD among
9. Heritability of attitudes: Twin research in religious perspective
10. Scholar finds parallels between U.S./Japanese attitudes toward wolves
11. Cranfield looks at recycling attitudes

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/28/2016)... 2016 "The biometric system ... The biometric system market is in the growth ... near future. The biometric system market is expected to ... a CAGR of 16.79% between 2016 and 2022. Government ... technology in smartphones, rising use of biometric technology in ...
(Date:11/22/2016)...   MedNet Solutions , an innovative SaaS-based eClinical ... research, is pleased to announce that the company has ... Sciences Awards as "Most Outstanding in eClinical Solutions" ... of recognition and growth for MedNet, which has effectively ... iMedNet ™ , MedNet,s flagship eClinical ...
(Date:11/17/2016)... , Nov. 17, 2016 Global Market Watch: ... Biobanks (Disease-Based Banks, Population-Based Banks and Academics) market is to ... for Private Biobanks shows the highest Compounded Annual Growth Rate ... region during the analysis period 2014-2020. North ... of 9.95% followed by Europe at ...
Breaking Biology News(10 mins):
(Date:11/30/2016)... , Nov. 30, 2016  GenomOncology today announced the ... President of Medical Affairs.  Dr. Coleman will ... the company,s proprietary knowledge-enabled platform. The GenomOncology software suite empowers ... genetic sequencing data and clinical decision support, from quality control ... , ...
(Date:11/30/2016)... - Portage Biotech Inc. ("Portage" or "the Company") (OTC: ... announce the formation of EyGen, Ltd. a new ... through proof of concept. EyGen,s lead asset is ... Limited and being developed for topical ophthalmic delivery ... diseases. This agent has the potential to become ...
(Date:11/30/2016)... 2016  The Allen Institute for Cell Science ... publicly available collection of gene edited, fluorescently tagged ... cellular structures with unprecedented clarity. Distributed through the ... are a crucial first step toward visualizing the ... makes human cells healthy and what goes wrong ...
(Date:11/30/2016)... Nov. 30, 2016  Tempus, a technology company ... and Penn,s Abramson Cancer Center have partnered to ... response to immunotherapy treatment based on next generation ... part of a research collaboration, Tempus will provide ... cancer patient data to Penn. Utilizing next-generation sequencing, ...
Breaking Biology Technology:
Cached News: